Advanced Therapy Medicinal Products CDMO Market Size, Share, Growth, and Industry Analysis, By Type (Gene Therapy, Cell Therapy, Tissue Engineered, Other Products), By Application (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Opthalmology, Haematology, Gasteroenterology, Other Indications), Regional Insights and Forecast to 2035

Advanced Therapy Medicinal Products CDMO Market Overview

The global Advanced Therapy Medicinal Products CDMO Market size estimated at USD 10734.7 million in 2026 and is projected to reach USD 61384.02 million by 2035, growing at a CAGR of 21.38% from 2026 to 2035.

The Advanced Therapy Medicinal Products CDMO Market is expanding rapidly due to increasing commercialization of gene therapies, cell therapies, and regenerative medicines across global healthcare systems. More than 2,450 active advanced therapy clinical trials were registered globally during 2025, with 41% focused on oncology applications. Gene therapy manufacturing accounted for 46% of CDMO outsourcing projects because viral vector production demand increased significantly. Cell therapy services represented 38% of global advanced therapy manufacturing activities during 2025. Automated bioprocessing systems improved manufacturing efficiency by 24% across contract development and manufacturing facilities. Single-use bioreactor adoption reached 57% of advanced therapy production operations due to contamination reduction and process flexibility benefits worldwide.

The United States represented 44% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because biotechnology innovation, regulatory approvals, and clinical trial activities remained highly concentrated nationwide. More than 1,120 active advanced therapy clinical programs were operational across U.S. biotechnology and pharmaceutical companies during 2025. Gene therapy manufacturing represented 49% of domestic CDMO outsourcing demand because viral vector capacity expansion accelerated significantly. Cell therapy projects accounted for 35% of U.S. advanced therapy manufacturing activities. Automated manufacturing platforms improved production scalability by 22% across domestic CDMO facilities. Regulatory fast-track designations increased by 18% between 2022 and 2025 for advanced therapy medicinal products across the United States.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Gene therapy manufacturing accounted for 46% of outsourcing demand, while oncology applications represented 41% of clinical activity and single-use bioprocessing systems contributed 57% of facility modernization projects.
• Major Market Restraint: Around 39% of manufacturers reported high production costs, while 34% identified regulatory complexity and 28% experienced limited large-scale viral vector manufacturing capacity.
• Emerging Trends: Automated bioprocessing systems represented 24% of innovation activities, single-use bioreactors accounted for 57% of production operations, and AI-assisted manufacturing analytics contributed 19% of technology upgrades.
• Regional Leadership: North America accounted for 44% of global Advanced Therapy Medicinal Products CDMO demand, Europe represented 31%, Asia-Pacific held 20%, and Middle East & Africa contributed 5%.
• Competitive Landscape: The top five CDMO providers controlled 52% of outsourced manufacturing activities, while viral vector specialists represented 47% of advanced therapy production contracts globally.
• Market Segmentation: Gene therapy manufacturing held 46% market share, cell therapy represented 38%, oncology applications accounted for 41% of outsourcing demand, and immunology indications contributed 12%.
• Recent Development: Viral vector manufacturing capacity expanded by 27% during 2024, automated cell processing systems increased by 22%, and AI-assisted manufacturing analytics adoption reached 19% globally.

Advanced Therapy Medicinal Products CDMO Market Latest Trends

The Advanced Therapy Medicinal Products CDMO Market is witnessing rapid technological transformation because biotechnology companies increasingly outsource complex manufacturing operations for cell therapies, gene therapies, and regenerative medicine products. Gene therapy manufacturing accounted for 46% of outsourced CDMO activities during 2025 because viral vector demand expanded significantly across clinical and commercial programs. Single-use bioreactor systems represented 57% of advanced therapy manufacturing operations because contamination control and process scalability became critical operational priorities.

Automated cell processing technologies improved manufacturing efficiency by 24% across CDMO production facilities during 2025. Artificial intelligence-assisted manufacturing analytics reduced production deviations by 18% across advanced therapy medicinal product operations. Viral vector manufacturing capacity increased by 27% during 2024 because more than 2,450 active clinical trials required scalable therapy production infrastructure. Personalized medicine development also became a major trend, with autologous cell therapies accounting for 33% of advanced therapy manufacturing activities globally during 2025. Cryopreservation technologies improved cellular product stability by 21% during international distribution operations. Cloud-based manufacturing monitoring systems represented 26% of digital infrastructure upgrades because remote production management and quality assurance became increasingly important across contract manufacturing facilities worldwide.

Advanced Therapy Medicinal Products CDMO Market Dynamics

DRIVER

"Rising demand for gene therapies and personalized medicines."

The increasing commercialization of gene therapies and personalized medicines is significantly driving the Advanced Therapy Medicinal Products CDMO Market. More than 2,450 advanced therapy clinical trials were active globally during 2025, with oncology applications representing 41% of total programs. Gene therapy manufacturing accounted for 46% of outsourcing contracts because biotechnology companies increasingly required viral vector production expertise. Automated bioprocessing technologies improved manufacturing efficiency by 24% across CDMO facilities. Personalized autologous cell therapies represented 33% of manufacturing demand during 2025 because precision medicine adoption expanded globally. Regulatory fast-track designations for advanced therapies increased by 18% between 2022 and 2025, accelerating commercial manufacturing requirements across biotechnology and pharmaceutical industries.

RESTRAINT

"High production costs and regulatory complexity."

High operational costs and complex regulatory requirements remain major restraints affecting the Advanced Therapy Medicinal Products CDMO Market. Around 39% of biotechnology companies identified manufacturing expenses as the primary outsourcing challenge during 2025. Viral vector production costs increased by 22% compared with conventional biologics manufacturing due to specialized facility requirements. Regulatory compliance activities represented 34% of operational complexity across advanced therapy production environments. Limited large-scale manufacturing capacity affected 28% of gene therapy commercialization projects globally. Skilled workforce shortages impacted 25% of CDMO facilities implementing automated cell processing technologies. Multi-country regulatory approval variations also delayed product commercialization timelines by 17% across international therapy development programs during 2025.

OPPORTUNITY

"Expansion of automated manufacturing and viral vector production."

Automated manufacturing systems and viral vector production infrastructure are creating strong opportunities in the Advanced Therapy Medicinal Products CDMO Market. Viral vector manufacturing capacity increased by 27% during 2024 because advanced therapy clinical pipelines expanded rapidly worldwide. Automated cell processing systems improved manufacturing scalability by 22% across commercial production facilities. Single-use bioreactors represented 57% of newly installed manufacturing equipment because contamination reduction and flexible batch processing became operational priorities. Artificial intelligence-assisted production analytics reduced manufacturing deviations by 18%. Asia-Pacific increased advanced therapy CDMO facility investments by 21% during 2025 because biotechnology infrastructure development accelerated rapidly across regional economies.

CHALLENGE

"Managing scalability and cold-chain logistics."

Scalability limitations and cold-chain logistics remain major challenges for advanced therapy medicinal product manufacturers. Around 31% of CDMO facilities experienced scalability constraints during commercial production expansion projects in 2025. Cryopreservation requirements increased distribution complexity by 23% across international therapy shipments. Autologous cell therapy manufacturing timelines extended by 18% because patient-specific production required highly customized workflows. Viral vector contamination risks affected 14% of large-scale production environments during 2025. Multi-site manufacturing coordination challenges increased operational delays by 16% across global supply chains. Temperature-controlled transportation infrastructure shortages impacted 19% of advanced therapy distribution operations worldwide during long-distance international deliveries.

Advanced Therapy Medicinal Products CDMO Market Segmentation

Download Free Sample to learn more about this report.

The Advanced Therapy Medicinal Products CDMO Market is segmented by therapy type and therapeutic application based on manufacturing complexity, outsourcing demand, and clinical development activity. Gene therapy manufacturing accounted for 46% of global market demand during 2025 because viral vector production requirements expanded significantly. Cell therapy services represented 38% of outsourced manufacturing activities due to rising personalized medicine adoption. Oncology applications contributed 41% of global CDMO demand because cancer immunotherapy development remained highly active worldwide. Immunology and inflammation applications accounted for 12% of market utilization during 2025. Single-use bioprocessing systems represented 57% of advanced therapy manufacturing infrastructure across global CDMO facilities.

BY TYPE

Gene Therapy: Gene therapy manufacturing dominated the Advanced Therapy Medicinal Products CDMO Market with 46% share during 2025 because viral vector production demand increased significantly across oncology and rare disease therapies. Oncology-related gene therapy projects represented 43% of segment utilization because precision cancer treatment programs expanded rapidly worldwide. Viral vector manufacturing capacity increased by 27% during 2024 across CDMO facilities. North America accounted for 48% of gene therapy outsourcing demand because biotechnology innovation remained highly concentrated across the region. Automated vector production technologies improved manufacturing efficiency by 24%. Single-use bioreactors represented 59% of gene therapy manufacturing infrastructure due to contamination control advantages during large-scale production activities.

Cell Therapy: Cell therapy manufacturing accounted for 38% of global market demand during 2025 because personalized medicine and regenerative treatment programs expanded significantly. Autologous cell therapies represented 33% of segment utilization because patient-specific treatment approaches gained regulatory and clinical acceptance worldwide. Automated cell processing systems improved production scalability by 22% across manufacturing facilities. Europe accounted for 29% of cell therapy outsourcing demand because regenerative medicine research activities expanded rapidly. Cryopreservation technologies improved cellular stability by 21% during transportation and storage operations. Artificial intelligence-assisted manufacturing analytics reduced process deviations by 18% during commercial cell therapy production activities globally during 2025.

Tissue Engineered: Tissue-engineered product manufacturing represented 11% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because regenerative medicine applications expanded across orthopedics and wound healing therapies. Musculoskeletal applications accounted for 37% of tissue-engineered manufacturing activities because cartilage and bone regeneration research accelerated significantly. Three-dimensional bioprinting technologies improved scaffold precision by 19% during tissue engineering processes. Asia-Pacific represented 24% of segment demand because regenerative healthcare infrastructure investments increased during 2025. Automated tissue culture systems reduced contamination risks by 16% across manufacturing facilities. Biomaterial integration technologies improved tissue durability by 18% during regenerative therapy production operations worldwide.

Other Products: Other advanced therapy medicinal products accounted for 5% of global market demand during 2025 because novel regenerative medicine platforms and hybrid therapies remained in early commercialization stages. Immunology applications represented 29% of this segment because advanced biologic therapies expanded across autoimmune disease treatment programs. Cloud-based manufacturing monitoring systems accounted for 26% of operational upgrades across specialized production facilities. North America represented 35% of segment utilization because biotechnology innovation activities remained highly concentrated. Automated quality assurance systems improved production consistency by 17% during advanced therapy manufacturing operations. Multi-platform therapy development technologies also expanded significantly across experimental regenerative medicine programs worldwide during 2025.

BY APPLICATION

Oncology: Oncology applications dominated the Advanced Therapy Medicinal Products CDMO Market with 41% share during 2025 because CAR-T therapies, tumor-infiltrating lymphocyte therapies, and gene-modified immunotherapies expanded rapidly across global clinical pipelines. More than 1,000 oncology-focused advanced therapy clinical programs were active worldwide during 2025. Gene therapy manufacturing accounted for 46% of oncology outsourcing contracts due to increasing viral vector demand. Automated cell processing systems improved manufacturing efficiency by 24% across oncology production facilities. North America represented 45% of oncology application demand because cancer immunotherapy approvals and biotechnology investments remained highly concentrated. Cryopreservation technologies improved treatment distribution stability by 21% during long-distance transportation activities.

Cardiology: Cardiology applications accounted for 8% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because regenerative therapies targeting heart failure, ischemic injury, and vascular disorders gained clinical traction. Stem cell-based cardiac therapies represented 34% of segment utilization during 2025. Tissue-engineered cardiovascular products improved regenerative treatment outcomes by 18% across clinical studies. Europe represented 29% of cardiology outsourcing demand because cardiovascular regenerative medicine research expanded significantly. Automated bioprocessing systems reduced manufacturing deviations by 17% during cardiac therapy production. Cryogenic storage technologies improved cellular viability by 19% across transportation and preservation operations during commercial-scale manufacturing activities worldwide.

Central Nervous System: Central nervous system applications represented 9% of global market demand during 2025 because advanced therapies targeting Parkinson’s disease, Alzheimer’s disease, spinal cord injuries, and rare neurological disorders advanced through clinical development. Gene therapy manufacturing accounted for 51% of CNS-related outsourcing projects due to rising demand for viral vector production infrastructure. Artificial intelligence-assisted analytics improved manufacturing precision by 16% during neurological therapy production. North America accounted for 42% of CNS application demand because biotechnology innovation and orphan drug research remained highly active. Automated quality assurance systems improved production consistency by 18% during large-scale CNS therapy manufacturing operations globally.

Musculoskeletal: Musculoskeletal applications accounted for 7% of global advanced therapy medicinal product manufacturing demand during 2025 because regenerative orthopedic therapies and tissue-engineered cartilage products expanded significantly. Tissue-engineered products represented 37% of musculoskeletal therapy manufacturing activities during 2025. Automated scaffold production technologies improved manufacturing precision by 19% across regenerative medicine facilities. Asia-Pacific represented 23% of segment demand because orthopedic healthcare infrastructure investments increased significantly. Stem cell-based bone regeneration therapies improved treatment recovery rates by 17% across clinical programs. Single-use bioreactors represented 49% of musculoskeletal production infrastructure because contamination control remained essential during regenerative tissue manufacturing.

Infectious Disease: Infectious disease applications represented 5% of global market demand during 2025 because advanced cell therapies and gene-modified immune treatments expanded across antiviral and antimicrobial research programs. Cell therapy manufacturing accounted for 32% of infectious disease outsourcing activities because immunotherapy-based treatments gained clinical importance. Automated viral vector production improved manufacturing efficiency by 18% during infectious disease therapy development. Europe represented 27% of application demand because advanced immunotherapy programs expanded significantly across biotechnology companies. Cryopreservation technologies improved biological stability by 16% during therapy transportation operations. Artificial intelligence-assisted manufacturing analytics reduced production variability by 14% during infectious disease biologic manufacturing activities worldwide.

Dermatology: Dermatology applications accounted for 4% of Advanced Therapy Medicinal Products CDMO demand during 2025 because regenerative skin therapies and tissue-engineered wound healing products expanded significantly across healthcare systems. Tissue-engineered skin substitutes represented 41% of dermatology-related manufacturing activities during 2025. Automated tissue culture systems improved production consistency by 17% across dermatological therapy facilities. North America accounted for 38% of dermatology outsourcing demand because regenerative wound care technologies advanced rapidly. Stem cell-based skin regeneration therapies improved treatment efficiency by 16% across clinical applications. Single-use manufacturing systems reduced contamination risks by 18% during dermatological advanced therapy production processes globally.

Endocrine and Metabolic: Endocrine and metabolic applications represented 6% of global advanced therapy outsourcing demand during 2025 because gene-editing therapies and stem cell-based metabolic disorder treatments expanded rapidly. Diabetes-related regenerative medicine programs accounted for 33% of segment utilization because pancreatic cell therapies gained clinical momentum. Automated cell processing systems improved manufacturing scalability by 19% during endocrine therapy production. Asia-Pacific represented 24% of endocrine outsourcing demand because metabolic disease prevalence increased significantly. Cryogenic preservation technologies improved cell viability by 18% during transportation and storage activities. Artificial intelligence-assisted process monitoring reduced production deviations by 15% during endocrine and metabolic therapy manufacturing worldwide.

Genetic Disorders: Genetic disorder applications accounted for 11% of global market demand during 2025 because rare disease therapies and gene-editing technologies expanded rapidly across biotechnology pipelines. Gene therapy manufacturing represented 58% of genetic disorder outsourcing contracts because viral vector production demand increased significantly. North America accounted for 47% of segment demand because orphan drug research and regulatory approvals remained highly concentrated. Automated viral vector production systems improved scalability by 23% during rare disease therapy manufacturing operations. Single-use bioreactors represented 61% of production infrastructure because flexible manufacturing remained essential for low-volume personalized therapies during 2025.

Immunology & Inflammation: Immunology and inflammation applications represented 12% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because autoimmune disease therapies and immune-modulating cell treatments advanced rapidly through commercialization pipelines. Cell therapy manufacturing accounted for 44% of segment outsourcing activities because immunomodulatory regenerative treatments gained significant clinical attention. Europe represented 31% of immunology-related manufacturing demand due to strong autoimmune disease research infrastructure. Automated quality control systems improved manufacturing precision by 18% during immunotherapy production. Cryopreservation technologies improved biologic stability by 19% during transportation operations. Artificial intelligence-assisted analytics reduced manufacturing inconsistencies by 16% during large-scale immunology therapy production globally.

Opthalmology: Opthalmology applications accounted for 3% of global advanced therapy medicinal product manufacturing demand during 2025 because retinal gene therapies and stem cell-based vision restoration programs expanded significantly. Gene therapy manufacturing represented 49% of ophthalmology outsourcing activities because retinal disorder treatments increasingly required viral vector delivery systems. North America represented 41% of segment demand because rare eye disease clinical programs accelerated rapidly. Automated manufacturing technologies improved production efficiency by 17% during retinal therapy development activities. Cryogenic storage systems improved cellular product preservation by 15% during long-distance transportation operations worldwide.

Haematology: Haematology applications accounted for 6% of global market demand during 2025 because advanced blood disorder therapies and hematopoietic stem cell treatments expanded significantly across healthcare systems. Gene therapy manufacturing accounted for 53% of haematology outsourcing activities because sickle cell disease and hemophilia therapies required large-scale viral vector production. Automated bioprocessing systems improved manufacturing consistency by 20% during hematological therapy production. Europe represented 28% of segment demand because blood disorder treatment programs expanded significantly during 2025. Single-use manufacturing systems reduced contamination risk by 17% across hematology-focused CDMO facilities globally.

Gasteroenterology: Gasteroenterology applications represented 4% of global advanced therapy medicinal products outsourcing demand during 2025 because regenerative gastrointestinal therapies and inflammatory bowel disease treatments advanced through clinical development stages. Cell therapy manufacturing represented 36% of segment utilization because regenerative intestinal therapies gained clinical traction. Asia-Pacific accounted for 22% of gastroenterology outsourcing demand because digestive disease treatment programs expanded significantly. Automated tissue culture systems improved manufacturing precision by 16% across gastrointestinal therapy production facilities. Cryogenic logistics technologies enhanced product stability by 15% during transportation activities worldwide.

Other Indications: Other indications accounted for 4% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because experimental regenerative medicine programs and multi-indication biologic therapies diversified across healthcare sectors. Rare disease therapies represented 31% of this segment because precision medicine innovation accelerated significantly. Automated manufacturing systems improved scalability by 18% across specialty therapy production operations. North America and Europe collectively represented 69% of outsourcing demand because biotechnology infrastructure and regulatory approvals remained highly concentrated across both regions. Artificial intelligence-assisted manufacturing analytics reduced operational deviations by 16% during advanced therapy production activities worldwide.

Advanced Therapy Medicinal Products CDMO Market Regional Outlook

Download Free Sample to learn more about this report.

The Advanced Therapy Medicinal Products CDMO Market demonstrates strong regional growth supported by biotechnology innovation, gene therapy commercialization, and regenerative medicine infrastructure expansion. North America accounted for 44% of global market demand during 2025 because biotechnology investment and clinical trial activity remained highly concentrated across the region. Europe represented 31% of market utilization due to strong regenerative medicine research and advanced healthcare manufacturing infrastructure. Asia-Pacific contributed 20% of global demand because biotechnology production facilities and contract manufacturing investments expanded significantly. Middle East & Africa accounted for 5% of installations supported by increasing healthcare modernization and biologics manufacturing projects during 2025.

NORTH AMERICA

North America dominated the Advanced Therapy Medicinal Products CDMO Market with 44% share during 2025 because biotechnology innovation, gene therapy commercialization, and regulatory approvals remained highly active across the region. The United States represented 89% of regional demand because more than 1,120 advanced therapy clinical programs were operational nationwide during 2025. Gene therapy manufacturing accounted for 49% of North American outsourcing activities because viral vector production capacity expansion accelerated significantly. Cell therapy manufacturing represented 35% of regional advanced therapy CDMO utilization due to increasing personalized medicine adoption. Automated bioprocessing systems improved manufacturing efficiency by 24% across regional facilities. Single-use bioreactors accounted for 57% of installed manufacturing infrastructure because contamination reduction and flexible processing remained operational priorities. Artificial intelligence-assisted analytics improved production consistency by 19% during advanced therapy manufacturing activities. Oncology applications represented 43% of regional outsourcing demand because cancer immunotherapy clinical development expanded significantly across biotechnology and pharmaceutical organizations during 2025.

EUROPE

Europe accounted for 31% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because regenerative medicine research and biotechnology manufacturing infrastructure remained highly developed across the region. Germany represented 24% of European demand because cell therapy and gene therapy production capabilities expanded significantly during 2024. Gene therapy manufacturing represented 44% of regional outsourcing activities due to increasing viral vector production requirements across clinical development programs. The United Kingdom and France collectively contributed 29% of regional market demand because advanced therapy clinical research and biologics manufacturing investments remained strong. Single-use bioprocessing systems accounted for 55% of European manufacturing infrastructure during 2025. Automated cell processing technologies improved production scalability by 22% across regional facilities. Cryopreservation technologies improved advanced therapy distribution efficiency by 21% across European logistics operations. Oncology and immunology applications collectively represented 53% of outsourcing demand because precision medicine development accelerated significantly during 2025.

ASIA-PACIFIC

Asia-Pacific represented 20% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because biotechnology infrastructure development and advanced therapy manufacturing investments accelerated rapidly across regional economies. China accounted for 39% of Asia-Pacific demand because gene therapy production and viral vector manufacturing facilities expanded significantly. Cell therapy manufacturing represented 36% of regional outsourcing activities because regenerative medicine programs increased during 2025. Japan contributed 21% of regional demand because stem cell therapy research and precision medicine development remained highly advanced. India increased advanced therapy CDMO investments by 23% between 2022 and 2025 because biotechnology manufacturing infrastructure expanded rapidly. Automated bioprocessing systems improved production efficiency by 20% across regional facilities. Single-use bioreactors represented 51% of installed manufacturing technologies due to contamination reduction benefits. Oncology applications accounted for 38% of Asia-Pacific outsourcing demand because cancer immunotherapy clinical programs expanded significantly across regional biotechnology organizations during 2025.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for 5% of global Advanced Therapy Medicinal Products CDMO demand during 2025 because biologics manufacturing infrastructure and regenerative medicine investments expanded steadily across the region. Saudi Arabia and the United Arab Emirates collectively represented 36% of regional demand because biotechnology infrastructure modernization projects increased significantly. Gene therapy manufacturing accounted for 41% of regional outsourcing activities because advanced rare disease treatment programs expanded across healthcare systems during 2025. South Africa contributed 18% of regional demand because clinical trial activities and biologics manufacturing investments increased during 2024. Automated manufacturing systems improved production scalability by 16% across regional advanced therapy facilities. Cryopreservation technologies enhanced international therapy distribution efficiency by 18% during long-distance transportation activities. Oncology applications represented 39% of regional outsourcing demand because cancer treatment innovation expanded significantly during 2025. Single-use bioprocessing systems also increased rapidly across regional biotechnology manufacturing facilities during advanced therapy infrastructure expansion projects.

List of Top Advanced Therapy Medicinal Products CDMO Companies

• Celonic
• Bio Elpida
• CGT Catapult
• Rentschler Biopharma SE
• AGC Biologics
• Catalent
• Lonza
• WuXi Advanced Therapies
• BlueReg
• Minaris Regenerative Medicine
• Patheon

List of Top 2 Companies Market Share

• Lonza: accounted for approximately 19% of global Advanced Therapy Medicinal Products CDMO out

  Advanced Therapy Medicinal Products CDMO Market Report Coverage

  REPORT COVERAGE	DETAILS
  Market Size Value In	USD 10734.7 Billion in 2026
  Market Size Value By	USD 61384.02 Billion by 2035
  Growth Rate	CAGR of 21.38% from 2026 - 2035
  Forecast Period	2026 - 2035
  Base Year	2025
  Historical Data Available	Yes
  Regional Scope	Global
  Segments Covered
  	By Type Gene Therapy Cell Therapy Tissue Engineered Other Products
  	By Application Oncology Cardiology Central Nervous System Musculoskeletal Infectious Disease Dermatology Endocrine Metabolic Genetic Immunology & Inflammation Opthalmology Haematology Gasteroenterology Other Indications